JBL

4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid

Find entries where: JBL

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
Identifiers	4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
Formula	C₂₁ H₁₅ N₃ O₄
Molecular Weight	373.362
Type	NON-POLYMER
Isomeric SMILES	c1ccc(c(c1)c2nc(n(n2)c3ccc(cc3)C(=O)O)c4ccccc4O)O
InChI	InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
InChIKey	BOFQWVMAQOTZIW-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	43
Chiral Atom Count	0
Bond Count	46
Aromatic Bond Count	23

Drug Info: DrugBank

DrugBank ID	DB01609
Name	Deferasirox
Groups	approved investigational
Description	Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms	Deferasiroxum Deferasirox
Brand Names	Sandoz Deferasirox Jadenu Deferasirox PMS-deferasirox (type J) PMS-deferasirox Sandoz Deferasirox (type J) Deferasirox (type J) Taro-deferasirox (type J) Teva-deferasirox Deferasirox Oral Granules Deferasirox oral Auro-deferasirox (type J) Apo-deferasirox (type J) Apo-deferasirox Deferasorox Taro-deferasirox Deferasirox Mylan Exjade Teva-deferasirox (type J) Deferasirox Accord
Indication	For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories	Acids, Carbocyclic Benzene Derivatives Benzoates Chelating Agents Compounds used in a research, industrial, or household setting Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Inducers Cytochrome P-450 CYP3A4 Inducers Cytochrome P-450 CYP3A4 Inducers (strength unknown) Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Enzyme Inhibitors Heavy Metal Antagonists Iron Chelating Activity Iron Chelating Agents Sequestering Agents Triazoles UGT1A1 Inhibitors UGT1A1 Substrates UGT1A3 Inhibitors UGT1A9 Inhibitors
ATC-Code	V03AC03
CAS number	201530-41-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Iron	-	unknown	chelator
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	inducer
UDP-glucuronosyltransferase 1-1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate,inhibitor
UDP-glucuronosyltransferase 1-3	MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE...	unknown	inhibitor
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	inhibitor
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource Name	Reference
PubChem	214348
ChEMBL	CHEMBL550348
ChEBI	CHEBI:49005
CCDC/CSD	QEKDUI, SAJFIT, SAJFIT01, QEKGAR, LAPVEF01, QEKFOE, LAPVEF
COD	7229079, 7229081, 7229080, 7229082, 2233779

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.

Prepare Data

Validate Data

Deposit Data

Help and Resources

JBL

4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid

Chemical Component Summary

Chemical Details

Drug Info: DrugBank

Drug Targets

Related Resource References